Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + HAG for induction in newly diagnosed adult ETP-ALL
ChiCTR2200061708Phase 2Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Composite complete remission after first induction. Started Jul 2022; status: completed.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2200061708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061708.